CAMBRIDGE, Mass. Tremeau Pharmaceuticals, Inc. (Tremeau), a new pharmaceutical company focused on providing non-opioid pain treatments for rare diseases, will present during the 2018 Biotech Showcase.
Tremeau’s CEO, Mr. Bradford C. Sippy, will present a corporate overview on January 8, 2018 at 9:15 AM PST. The presentation will be held at the Hilton San Francisco Union Square Ballroom Level Franciscan B in San Francisco, California.
To view the live webcast, please use the following link: www.tremeaurx.com/news-1. An archived version of the webcast will be available for up to 12 months on the Company website.
The Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences.
About Tremeau Pharmaceuticals, Inc.
Tremeau is a new pharmaceutical company focused on providing non-opioid pain treatments for rare diseases and other unique patient conditions with no approved treatments. Tremeau’s unique approach to acute and chronic pain in rare diseases is rooted in the mechanism of action, documented efficacy, and clinically differentiated profile of COX-2 selective NSAIDs.
For additional information about Tremeau, please visit www.tremeaurx.com.